Breaking News: The application submitted by our agency to convert the prescription drug “Yinhuang Containing Oral Drops” into an over-the-counter (OTC) drug has been approved and publicly announced by the National Medical Products Administration.

Release time:

2023-06-21

Source:

Author:

Our company’s application to convert the prescription drug “Yinhuang Containing Oral Drops” into an over-the-counter (OTC) drug has been approved and publicly announced by the National Medical Products Administration.

On June 20, 2023, we learned from the National Medical Products Administration that the application submitted by our company, Rico International (Beijing) Medicine Technology Co., Ltd., to convert the traditional Chinese medicine product (Yinhuang Containing Dissolving Droplets) manufactured by Shanxi Qianhui Pharmaceutical Co., Ltd. from a prescription drug to an over-the-counter drug has been approved and publicly announced by the NMPA. From project initiation to public approval, this project took only a few months. The entire review process was smooth and without any supplementary submissions, fully demonstrating our company’s project team’s extensive experience and strong capabilities in drug conversion.

Our company’s project team for converting prescription drugs to over-the-counter (OTC) medications boasts many years of experience in prescription drug approval assessment, pharmacodynamic evaluation, literature retrieval and analysis, drafting and reviewing conversion documents, and has achieved numerous successful cases of switching from prescription to OTC status. We maintain excellent communication with the review experts at the China Drug Evaluation Center (CDR).

We welcome colleagues who are considering converting prescription drugs into over-the-counter medications to reach out for consultation. Ruike Pharmaceutical will provide you with comprehensive, accurate, and high-quality technical services.

Ruike International Pharmaceutical
June 21, 2023

Recommended News

03-06